A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance
Phase of Trial: Phase 0
Latest Information Update: 08 Aug 2014
At a glance
- Drugs NM 504 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms ProCo-Metformin
- Sponsors MicroBiome Therapeutics
- 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Dec 2013 MicroBiome Therapeutics completed bridge financing intended to support completion of this trial, according to a company media release.
- 22 Sep 2013 New trial record